Topic: vaccine development
Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.
Inovio's South Korean partner GeneOne plans to start a phase 1/2 study in South Korea in the third quarter.
Here is some other vaccine news of note for the week.
GSK and Merck will still lead as the top vaccine makers in 2024, according to a new report, while Sanofi and Pfizer are expected to swap positions.
Looking to take on global vaccine heavyweights, SutroVax revs up with Series C funding and a prominent new chairman.
Valneva is seeking a partner for a Lyme disease vaccine development effort it expects will cost $350 million.
With MERS and Lassa fever projects funded, the outbreak-focused alliance is ready to put a check mark beside the third disease on its priority list.
Pfizer is counting on some later-stage shots to carry the torch after its blockbuster Prevnar slows down. But it's stocking its early pipeline, too.
The International AIDS Vaccine Initiative will use grant funding to develop a Lassa vaccine based on the VSV vector.
VBI-1501 showed neutralizing antibody activities against both fibroblast and epithelial cell infections.